Skip to main content
Free research Free research Free target review with research home and workspace preview
Quick search ChEMBL 36
Loading Target Snapshot...
Querying ChEMBL database. This may take a few seconds.
Target Snapshot

CHEMBL5334 Target Snapshot

Non-receptor tyrosine-protein kinase TNK1 · SINGLE PROTEIN · Homo sapiens

998Compounds
153Assays
20Approved Drugs
495.0Activities
Free Research Context

Research home keeps recent targets

This target will appear in recent viewed items on this browser. Use the demo workspace to preview watch rules and decision queues.

Navigation

Switch target

Move to another high-traffic target or paste a specific ChEMBL target ID.

Broader Open DB context

Frame the target before identity details

Structured disease, protein, and project context should read before the lower-level identity rail.

As of 2026-09-13

Protein identity stays anchored to UniProt Q13470. Use UniProt Q13470 as the stable identity anchor, then attach disease evidence before program review.

Review focus
Protein anchor ready

Use UniProt Q13470 as the stable identity anchor, then attach disease evidence before program review.

ChEMBL component mapping + Open Targets-ready proxy + ChEMBL 36 via Core Engine 2026-09-13
Open source guide
Identity Layer

Cross-source identity

Keep the review anchor, source IDs, and context contract aligned before reusing this target elsewhere.

This review treats Non-receptor tyrosine-protein kinase TNK1 as ChEMBL target CHEMBL5334, mapped to UniProt Q13470. Disease framing currently uses the Open Targets-ready proxy contract.

Review anchor
Non-receptor tyrosine-protein kinase TNK1
SINGLE PROTEIN · Homo sapiens
As of 2026-09-13
ChEMBL target ID
CHEMBL5334
Primary anchor for compounds, assays, approvals, and exports
ChEMBL 36 via Core Engine As of 2026-09-13
www.ebi.ac.uk
UniProt accession
Q13470
Non-receptor tyrosine-protein kinase TNK1
UniProt accession via ChEMBL component mapping As of 2026-09-13
www.uniprot.org
Disease evidence contract
Open Targets-ready proxy
ChEMBL drug mechanism + indication proxy
ChEMBL drug mechanism + indication proxy As of 2026-09-13
www.ebi.ac.uk

Reuse the same identifiers in notes, watch rules, exports, and review packs so provenance stays stable across surfaces.

Source Guidance

Start with the right source

Choose the first block or source based on the question you are trying to answer.

Need stable target naming and protein identity?
UniProt Target Context
UniProt accession via ChEMBL component mapping

Start here when your first question is whether Non-receptor tyrosine-protein kinase TNK1 is the right protein anchor across sources, using UniProt Q13470 as the stable mapping.

Jump to Protein Context
Need disease fit before discussing compounds?
Disease Relevance & Evidence Level
ChEMBL drug mechanism + indication proxy

Use this block first when you need the strongest disease program and evidence level in one place.

Jump to Disease Context
Need a meeting-ready explanation of why this target matters?
Evidence Card
Review-ready rationale with source-aware context

Open the one-page evidence card when you want the rationale, activity base, and attribution together.

Open Review-ready Card
Overview

Basic Information

Verify identity, organism, and the fastest next research jumps from the same page.

UniProt Context

UniProt Target Context

Reviewable protein naming and mapping context for this target snapshot.

Protein LabelNon-receptor tyrosine-protein kinase TNK1
UniProt AccessionQ13470
Component TypeProtein
Sequence Length666 aa

Non-receptor tyrosine-protein kinase TNK1

Source · UniProt accession via ChEMBL component mapping
Review Cue

How to read this target

Review this target as Non-receptor tyrosine-protein kinase TNK1, mapped to UniProt Q13470. Sequence length is 666 aa.

Mapped IDQ13470
Review nameNon-receptor tyrosine-protein kinase TNK1
OrganismHomo sapiens
Clinical Profile

Clinical Phase Distribution

20
Approved
6
Phase III
14
Phase II
10
Phase I
Assay Mix

Activity Type Distribution

IC50118.0
KD377.0
Lead Set

Top Inhibitors (by pChEMBL)

ChEMBL IDpChEMBLTypeValue (nM)Phase
CHEMBL388978 9.23 IC50 0.584 Preclinical
CHEMBL5772004 8.86 IC50 1.37 Preclinical
CHEMBL509032 8.74 Kd 1.8 Preclinical
CHEMBL388978 8.6 Kd 2.5 Preclinical
CHEMBL5756581 8.56 IC50 2.77 Preclinical
CHEMBL3545085 8.52 Kd 3.0 Preclinical
CHEMBL5853387 8.48 IC50 3.33 Preclinical
CHEMBL6022678 8.47 IC50 3.36 Preclinical
CHEMBL6058132 8.45 IC50 3.59 Preclinical
CHEMBL5993654 8.41 IC50 3.92 Preclinical
Distribution

pChEMBL Value Distribution

6
5.0
23
5.5
24
6.0
13
6.5
39
7.0
64
7.5
26
8.0
8
8.5
1
9.0
0
9.5
pChEMBL
Approved Drugs

Approved Drugs

PACRITINIB
CHEMBL2035187
Approved 2022
FEDRATINIB
CHEMBL1287853
Approved 2019
GILTERITINIB
CHEMBL3301622
Approved 2018
FOSTAMATINIB
CHEMBL2103830
Approved 2018
BARICITINIB
CHEMBL2105759
Approved 2017
MIDOSTAURIN
CHEMBL608533
Approved 2017
NINTEDANIB
CHEMBL502835
Approved 2014
CERITINIB
CHEMBL2403108
Approved 2014
DABRAFENIB
CHEMBL2028663
Approved 2013
AXITINIB
CHEMBL1289926
Approved 2012
TOFACITINIB
CHEMBL221959
Approved 2012
TOFACITINIB CITRATE
CHEMBL2103743
Approved 2012
PONATINIB
CHEMBL1171837
Approved 2012
CRIZOTINIB
CHEMBL601719
Approved 2011
PAZOPANIB
CHEMBL477772
Approved 2009
SUNITINIB
CHEMBL535
Approved 2006
DASATINIB
CHEMBL5416410
Approved 2006
ERLOTINIB
CHEMBL553
Approved 2004
Assay Landscape

Assay Landscape

153
Total Assays
184
Tested Compounds
1
Assay Types
Binding — 153 assays, 184 compounds
BAO Format Assays Compounds Avg pChEMBL
single protein format 114 141 7.4
assay format 25 3 8.0
cell-based format 8 1 5.0
subcellular format 6 39 6.5

Confidence Score Distribution

Source · ChEMBL 36 via Core Engine